Media coverage about Bio-Techne (NASDAQ:TECH) has trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bio-Techne earned a daily sentiment score of 0.24 on Accern’s scale. Accern also assigned press coverage about the biotechnology company an impact score of 44.8485147968217 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have impacted Accern’s scoring:
- Bio-Techne expands RNAscope in situ hybridization automation to facilitate drug R&D (pharmabiz.com)
- Bio-Techne (TECH) Coverage Initiated at Wells Fargo (americanbankingnews.com)
- Bio-Techne expands automation capabilities of popular RNAscope ISH technology (news-medical.net)
- Analyzing Bio-Techne (TECH) & Osiris Therapeutics (OSIR) (americanbankingnews.com)
Several analysts have recently issued reports on the company. ValuEngine raised Bio-Techne from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. BidaskClub raised Bio-Techne from a “buy” rating to a “strong-buy” rating in a report on Friday, March 16th. Deutsche Bank set a $163.00 target price on Bio-Techne and gave the stock a “buy” rating in a report on Thursday, March 1st. Zacks Investment Research raised Bio-Techne from a “hold” rating to a “buy” rating and set a $148.00 target price on the stock in a report on Saturday, February 10th. Finally, Craig Hallum reaffirmed a “buy” rating and issued a $160.00 price objective (up from $140.00) on shares of Bio-Techne in a research note on Wednesday, February 7th. One investment analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. Bio-Techne has a consensus rating of “Buy” and a consensus target price of $148.60.
Bio-Techne (NASDAQ:TECH) last released its quarterly earnings data on Tuesday, February 6th. The biotechnology company reported $1.02 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.10. The business had revenue of $154.15 million for the quarter, compared to analyst estimates of $145.93 million. Bio-Techne had a return on equity of 14.39% and a net margin of 19.17%. Bio-Techne’s revenue was up 16.9% compared to the same quarter last year. During the same period last year, the firm posted $0.81 earnings per share. analysts anticipate that Bio-Techne will post 4.01 EPS for the current fiscal year.
In related news, Director Charles A. Dinarello sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $136.06, for a total value of $680,300.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 3.40% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Bio-Techne (TECH) Share Price” was originally posted by Week Herald and is the property of of Week Herald. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://weekherald.com/2018/04/23/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-bio-techne-tech-share-price.html.
Bio-Techne Company Profile
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates through three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers native and recombinant proteins, monoclonal and polyclonal antibodies, immunoassays, biologically active chemical compounds, and in situ genomic hybridization assays for the research and clinical diagnostics markets.
Receive News & Ratings for Bio-Techne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Techne and related companies with MarketBeat.com's FREE daily email newsletter.